Janet Hammond

Janet is an expert in virology with a proven track record in antiviral therapeutic drug discovery and development. Janet has more than 20 years of broad and deep pharmaceutical and biopharmaceutical experience including clinical development program leadership and responsibilities for product discovery and translational activities, product life cycle management, medical affairs, safety, and pharmacovigilance.

Before joining Atea, Janet served as Vice President and Therapeutic Area Head for General Medicine and Infectious Disease Development at AbbVie. Prior to that, Janet served as Senior Vice President, Global Head of Infectious Diseases, and Head of pRED China at F. Hoffmann-La Roche. Earlier, she served as Chief Medical Officer, Senior Vice President, and Head of Medical Affairs at Valeant Pharmaceuticals and as Group Director in Global Clinical Research, Virology, and Infectious Diseases at Bristol-Myers Squibb. Janet began her career in drug discovery and development at GlaxoSmithKline where she rose through a series of clinical leadership positions to become Head of Clinical Drug Discovery, Virology.

Janet holds an M.D. and Ph.D. from the University of Cape Town, South Africa, and a Sc.M. in Clinical Investigation from Johns Hopkins University School of Hygiene and Public Health. Janet is a Fellow of the South African College of Physicians in Internal Medicine. Janet trained as a Clinical Fellow in the Division of Infectious Diseases at Duke University and as a Post Doctoral Clinical and Research Fellow in the Divisions of Clinical Pharmacology and Infectious Diseases at John Hopkins University School of Medicine.